Appointed Director

Raymond Goodrich, PhD, is a tenured professor in the department of microbiology, immunology and pathology at Colorado State University. In addition, he serves as in adjunct position as a professor of chemistry at The Ohio State University.

Goodrich’s research focuses on the prevention of transfusion-transmitted diseases, the development of new vaccine production methods for infectious diseases of animals and humans, and the development of novel cancer immunotherapy treatments for patients with solid organ tumors. Throughout this career, Goodrich has been awarded more than 58 patents and has co-authored more than 200 peer-reviewed articles and abstracts.

In his research, Goodrich uses new methods to stimulate immune response in patients with cancer and to prevent infectious diseases. A clinical application of new technology developed in his lab is for treatment of patients with advanced-stage ovarian cancer. In addition, his research group is focused on developing methods to generate new vaccine candidates for infectious diseases. His current program of work has been funded by the NIH/NIAID, BARDA and the U.S. Department of Defense and includes research on new vaccine formulations for SARS-CoV-2, tuberculosis, influenza and African swine fever.

Goodrich served as the executive director of the Infectious Disease Research Center at Colorado State University from 2016 to 2023. Prior to this, he spent 30 years in the private sector, leading research groups in the development of medical devices and products for collection, processing and preservation of blood and tissues and for the prevention of disease transmission by blood products.

Goodrich is the recipient of an honorary order of military medical merit and the Colorado State University Award for Innovative Excellence (2021). He serves as a member of the HHS Advisory Committee on Blood and Tissue Safety and Availability and the advisory board for the School of Biomedical Engineering at Colorado State University. He is also a member of the AABB Public Policy and Strategy Committee.